Interestingly, post-tests revealed that the CXCL1 mRNA level was significantly reduced only in the CRS-GCG group compared to that in the CRS-vehicle group (Figure 5a), suggesting the synergistic effect of Gln, Curcuméga® and Gabolysat® bioactive peptides on this parameter. This evidence concerns the gene CXCL1 and congenital rubella syndrome.